Medical News / News Coverage from AHA 2023: Lepodisiran, a Small Intefering RNA, Could Lower Lp(a) by More than 95%

Results from a phase 1 trial of lepodisiran, a short interfering RNA directed at hepatic synthesis of apolipoprotein(a), indicates use of the 608 mg formulation of the agent was associated with a 97% in lipoprotein(a) [Lp(a)]. Presented at the American Heart Association Scientific Sessions 2023 by Steve Nissen, MD, chief academic officer of the Heart Vascular & Thoracic Institute at Cleveland Clinic, results of the trial provide insight into the safety and efficacy of 6 dosages of lepodisiran relative to placebo therapy for lowering Lp(a) in adults without cardiovascular disease and with Lp(a) serum concentrations of 75 nmol/L or greater. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

New research into the speed of diagnosis of hypertrophic cardiomyopathy in the United States is providing ... read more
In a recent study, a smartphone app using artificial intelligence (AI) predicted heart failure 3 weeks ... read more
Reducing sodium in diet to 4,000 mg/day significantly lowers blood pressure after 1 week, a new ... read more
On November 12, 2023, Lexicon Pharmaceuticals, Inc. announced a post hoc analysis of clinical data from ... read more